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10−15% of mutations in the CFTR gene affect its correct splicing. The disease
severity in patients carrying these mutations is highly variable, correlated with
the level of aberrantly spliced transcripts. We aim to develop a splicing mutation-
speciﬁc therapy using antisense oligonucleotides (AOs), to modulate the splicing
pattern in patients carrying common splicing mutations. We focused on a common
splicing mutation, the 3849+10kb C-to-T, which leads to inclusion of an 84 bp
cryptic exon between exons 22−23 in the mature mRNA. This cryptic exon contains
an in-frame stop codon that leads to degradation of a signiﬁcant fraction of
the mRNA by the NMD pathway as well as to the production of prematurely
truncated nonfunctional proteins. We designed 4 2′-O-methyl phosphorothioate-
modiﬁed AOs, targeted to prevent the recognition of enhancer splice motifs in the
cryptic exon or to mask the junctions between this exon and its ﬂanking sequences.
Epithelial cell line established from a nasal polyp of a CF patient carrying the
3849+10kb C-to-T mutation was transfected with 2 of the designed AOs. AOs-
treated cells showed a highly signiﬁcant decrease in the level of aberrantly spliced
CFTR mRNA, along with a signiﬁcant increase in normal spliced CFTR mRNA
levels, reﬂecting transcripts that under normal conditions are degraded by the NMD
pathway. These results indicate that AOs targeted to mask splicing motifs around
the cryptic exon generated due to the 3849+10kb C-to-T splicing mutation, can
modulate increase the correct splicing. Further studies are required to investigate
whether these AOS can restore the CFTR function and improve patients’ clinical
state.
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Objectives: Cystic ﬁbrosis (CF) is a recessive genetic disease caused by non-
functional chloride and bicarbonate ion transport via CFTR. Mucus stagnation
occurs because the mucociliary clearance system is compromized, leading to lung
infections and damage. Using an explant system, we found that, in contrast to
normal mucus, the mucus of the small intestine is attached to the epithelium in
mice with a non-functional CFTR (CftrDF508). This could be reverted to a non-
attached phenotype by 100mM bicarbonate.
OligoG CF-5/20 is a natural product derived from alginate comprised of mainly
guluronate oligomers, with average length of 13 monomers. Previous studies have
shown that this oligomer alters the rheology of mucin/alginate gels, mucin/DNA
gels and CF sputum. Because of this, OligoG is being tested as an inhalation therapy
on CF patients. We have now tested OligoG on mouse ileum CF mucus.
Methods: Explants from the small intestine of CftrD508 mutant mice were mounted
in the horizontal Ussing-type chamber. OligoG (1%, 1.2%, 1.5%, 2%, 3% or 6%)
was added to the apical buffer, pH of 7.4. The attachment of the already formed
mucus was assessed by comparing the total mucus thickness before and after
aspiration.
Results: OligoG at 1.5% or higher normalized the mucus phenotype without
increase in mucus thickness. At 1% OligoG the mucus remained attached and
at 1.2% an intermediate phenotype was observed.
Conclusion: The effects are likely due to OligoG’s known ability to chelate calcium.
These observations indicate how OligoG could work in CF patients by normalizing
mucus layers in both the gut and potentially the lungs, at therapeutically relevant
concentrations.
